Want to see ANTX full AI Analyst Report?
AN2 Therapeutics, Inc. (ANTX) Stock Statistics & Valuation Metrics
Total Valuation
AN2 Therapeutics, Inc. has a market cap or net worth of $150.94M. The enterprise value is $138.26M.
- Market Cap
- $150.94M
- Enterprise Value
- $138.26M
Share Statistics
AN2 Therapeutics, Inc. has 37,736,237 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 37,736,237
- Owned by Insiders
- 14.96%
- Owned by Institutions
- 55.71%
Financial Efficiency
AN2 Therapeutics, Inc.’s return on equity (ROE) is -0.66 and return on invested capital (ROIC) is -71.59%.
- Return on Equity (ROE)
- -0.66
- Return on Assets (ROA)
- -0.57
- Return on Invested Capital (ROIC)
- -71.59%
- Return on Capital Employed (ROCE)
- -0.72
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.67M
- Employee Count
- 21
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of AN2 Therapeutics, Inc. is -4.30. AN2 Therapeutics, Inc.’s PEG ratio is -0.24.
- PE Ratio
- -4.30
- PS Ratio
- 0.00
- PB Ratio
- 2.44
- Price to FCF
- -4.96
- Price to Operating Cash Flow
- -6.07
- PEG Ratio
- -0.24
Income Statement
In the last 12 months, AN2 Therapeutics, Inc. had revenue of 0 and earned -35.17M in profits. Earnings per share was -1.16.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -38.11M
- Pretax Income
- -35.17M
- Net Income
- -35.17M
- EBITDA
- -35.17M
- Earnings Per Share (EPS)
- -1.16
Cash Flow
In the last 12 months, operating cash flow was -30.41M and capital expenditures 0, giving a free cash flow of -30.41M billion.
- Operating Cash Flow
- -30.41M
- Free Cash Flow
- -30.41M
- Free Cash Flow per Share
- -0.66
Dividends & Yields
AN2 Therapeutics, Inc. pays an annual dividend of $0.66, resulting in a dividend yield of ―
- Dividend Per Share
- $0.66
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -20.06%
- Earnings Yield
- -18.83%
Stock Price Statistics
- Beta
- -0.15
- 52-Week Price Change
- 257.14%
- 50-Day Moving Average
- 4.75
- 200-Day Moving Average
- 4.19
- Relative Strength Index (RSI)
- 44.00
- Average Volume (3m)
- 265.28K
Important Dates
AN2 Therapeutics, Inc. upcoming earnings date is Mar 31, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 31, 2027
- Ex-Dividend Date
- Jan 11, 2018
Financial Position
AN2 Therapeutics, Inc. as a current ratio of 6.87, with Debt / Equity ratio of 0.00%
- Current Ratio
- 6.87
- Quick Ratio
- 6.87
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.57
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, AN2 Therapeutics, Inc. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
AN2 Therapeutics, Inc. EV to EBITDA ratio is -3.56, with an EV/FCF ratio of -4.32.
- EV to Sales
- 0.00
- EV to EBITDA
- -3.56
- EV to Free Cash Flow
- -4.32
- EV to Operating Cash Flow
- -4.32
Balance Sheet
AN2 Therapeutics, Inc. has $64.40M in cash and marketable securities with $0.00 in debt, giving a net cash position of $64.40M billion.
- Cash & Marketable Securities
- $64.40M
- Total Debt
- $0.00
- Net Cash
- $64.40M
- Net Cash Per Share
- $1.71
- Tangible Book Value Per Share
- $1.64
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for AN2 Therapeutics, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 13.97%
Scores
- Smart Score
- 9
- AI Score
- 44
